港股异动 | 康诺亚-B(02162)高开逾4% 司普奇拜单抗注射液纳入国家基本医疗保险药品目录

智通财经网2025-12-08

智通财经APP获悉，康诺亚-B(02162)高开逾4%，截至发稿，涨4.23%，报61.6港元，成交额132.44万港元。消息面上，12月7日，康诺亚宣布，公司自主研发的国家1类新药康悦达®(司普奇拜单抗注射液)纳入《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》(“国家基本医疗保险药品目录”)，该目录将自2026年1月1日起正式实施。据介绍，康悦达®(司普奇拜单抗)是国内首个自主...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2589680731?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-08 09:24","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2589680731","market":"fut","top_or_hot":-1,"title":"港股异动 | 康诺亚-B(02162)高开逾4% 司普奇拜单抗注射液纳入国家基本医疗保险药品目录","media":"智通财经网","content":"<div>\n<p>智通财经APP获悉，康诺亚-B(02162)高开逾4%，截至发稿，涨4.23%，报61.6港元，成交额132.44万港元。消息面上，12月7日，康诺亚宣布，公司自主研发的国家1类新药康悦达®(司普奇拜单抗注射液)纳入《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》(“国家基本医疗保险药品目录”)，该目录将自2026年1月1日起正式实施。据介绍，康悦达®(司普奇拜单抗)是国内首个自主...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1378590.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 康诺亚-B(02162)高开逾4% 司普奇拜单抗注射液纳入国家基本医疗保险药品目录</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 康诺亚-B(02162)高开逾4% 司普奇拜单抗注射液纳入国家基本医疗保险药品目录\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-08 09:24 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1378590.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，康诺亚-B(02162)高开逾4%，截至发稿，涨4.23%，报61.6港元，成交额132.44万港元。消息面上，12月7日，康诺亚宣布，公司自主研发的国家1类新药康悦达®(司普奇拜单抗注射液)纳入《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》(“国家基本医疗保险药品目录”)，该目录将自2026年1月1日起正式实施。据介绍，康悦达®(司普奇拜单抗)是国内首个自主...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1378590.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1378590.html","article_id":"2589680731","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589680731","pubTimestamp":1765157099,"columns":[],"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，康诺亚-B高开逾4%，截至发稿，涨4.23%，报61.6港元，成交额132.44万港元。消息面上，12月7日，康诺亚宣布，公司自主研发的国家1类新药康悦达纳入《国家基本医疗保险、生育保险和工伤保险药品目录》，该目录将自2026年1月1日起正式实施。据介绍，康悦达是国内首个自主研发并获批上市的IL-4Rα人源化单克隆抗体，通过双重阻断IL-4/IL-13信号通路，精准抑制2型炎症疾病进展。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1583":"高瓴概念","BK1574":"生物医药B类股","BK1161":"生物科技","02162":"康诺亚-B","BK1587":"次新股"},"translate_title":"Changes in Hong Kong stocks | Connoya-B (02162) opened more than 4% higher and sprocibizumab injection was included in the national basic medical insurance drug list","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":1.5},"content_text":"智通财经APP获悉，康诺亚-B(02162)高开逾4%，截至发稿，涨4.23%，报61.6港元，成交额132.44万港元。消息面上，12月7日，康诺亚宣布，公司自主研发的国家1类新药康悦达®(司普奇拜单抗注射液)纳入《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》(“国家基本医疗保险药品目录”)，该目录将自2026年1月1日起正式实施。据介绍，康悦达®(司普奇拜单抗)是国内首个自主研发并获批上市的IL-4Rα人源化单克隆抗体，通过双重阻断IL-4/IL-13信号通路，精准抑制2型炎症疾病进展。康悦达®(司普奇拜单抗)目前已获批3项适应症：外用药控制不佳或不适合外用药治疗的成人中重度特应性皮炎、糖皮质激素治疗和/或手术治疗控制不佳的慢性鼻窦炎伴鼻息肉、鼻用糖皮质激素联合抗组胺药物治疗后症状控制不佳的成人中重度季节性过敏性鼻炎，3项适应症均已纳入新版国家基本医疗保险药品目录。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589680731","isCrawlerRequest":true}